Ancient Chinese Herbal Formula Targets Triple-Negative Breast Cancer via PPARγ Pathway
Erzhi Pill, a traditional Chinese medicine, shows potent anti-tumor effects in triple-negative breast cancer by activating the PPARγ signaling pathway.
Summary
Researchers investigated Erzhi Pill (EZP), a traditional Chinese herbal formula, as a potential treatment for triple-negative breast cancer (TNBC) — one of the most aggressive and difficult-to-treat cancer subtypes. Using a combination of serum pharmacochemistry, metabolomics, and laboratory experiments, the team identified key bioactive compounds including isorhamnetin, fisetin, and ursonic acid. EZP-containing serum dose-dependently suppressed TNBC cell proliferation, migration, and epithelial-mesenchymal transition while promoting apoptosis. The PPARγ signaling pathway, activated via the enzyme CES1, was identified as the central mechanism. In mouse xenograft models, high-dose EZP performed comparably to cisplatin, a standard chemotherapy agent, suggesting meaningful translational potential for this multi-target herbal approach.
Detailed Summary
Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, making it unresponsive to most targeted therapies and leaving patients with limited treatment options. Identifying novel, multi-target therapeutic strategies is an urgent clinical priority. Erzhi Pill (EZP), a classical Traditional Chinese Medicine formula historically used for various cancers, has shown general antitumor potential, but its specific mechanisms against TNBC were previously unknown.
This study employed a sophisticated multi-omics approach combining serum pharmacochemistry (UHPLC-Q Exactive HFX-MS), GC-MS-based metabolomics, and bioinformatics to map EZP's bioactive constituents and their molecular targets in TNBC. EZP-containing serum was applied to TNBC cells at concentrations of 0%, 5%, 10%, and 20%, with proliferation, migration, apoptosis, and epithelial-mesenchymal transition (EMT) assessed through standard assays including CCK-8, wound healing, Transwell, flow cytometry, and Western blot.
Key results showed that EZP dose-dependently inhibited TNBC cell proliferation, migration, and EMT while promoting apoptosis. Metabolomic profiling identified three principal bioactive compounds — isorhamnetin, fisetin, and ursonic acid — and revealed significant perturbations in lipid metabolism pathways, particularly the PPAR signaling pathway. Bioinformatics analysis indicated EZP activates PPARγ through CES1. Critically, pharmacological inhibition of PPARγ using GW9662 reversed EZP's anti-tumor effects, confirming PPARγ as the central mediator. In vivo xenograft experiments demonstrated tumor suppression comparable to cisplatin at high doses.
These findings position EZP as a promising multi-target therapeutic candidate for TNBC, with a mechanistically validated pathway. The PPARγ axis, increasingly recognized in cancer metabolism and immune regulation, represents a compelling druggable target.
Caveats include reliance on cell lines and mouse models, with no human clinical data yet available. The complexity of herbal formulas also makes standardization and regulatory approval challenging.
Key Findings
- EZP dose-dependently inhibited TNBC cell proliferation, migration, and EMT while promoting apoptosis in vitro.
- Key bioactive compounds identified: isorhamnetin, fisetin, and ursonic acid.
- EZP activates the PPARγ signaling pathway via the enzyme CES1, confirmed by PPARγ inhibitor reversal experiments.
- High-dose EZP showed tumor-suppressive efficacy comparable to cisplatin in mouse xenograft models.
- GC-MS metabolomics revealed significant lipid metabolism pathway perturbations as a core mechanism.
Methodology
The study used UHPLC-Q Exactive HFX-MS and GC-MS metabolomics combined with bioinformatics to identify bioactive compounds and targets. In vitro assays (CCK-8, Transwell, flow cytometry, Western blot) evaluated cellular effects of EZP-containing serum at multiple concentrations. In vivo efficacy was confirmed in a mouse xenograft model, with mechanistic validation using the PPARγ inhibitor GW9662.
Study Limitations
The study relies entirely on cell line and mouse xenograft models, with no human clinical validation. Herbal formula complexity poses challenges for standardization, dosing consistency, and regulatory approval. The abstract does not detail pharmacokinetics or potential toxicity profiles of EZP constituents.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.